Indeed, gain-of-function SHOC2 mutations have been linked to RASopathies, a group of clinical pathologies associated with dysregulated RAS/MAPK signaling such as Noonan syndrome and patients with these syndromes are predisposed to certain cancers [99–101]. This evidence concerns the gene SHOC2 and cancer.